iRhythm completes acquisition of VitalConnect
The transaction included $237.5 million in cash subject to customary adjustments and up to 423,334 shares; iRhythm separately provided $10.0 million in working capital funding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
iRhythm Holdings, Inc. (IRTC) completed its acquisition of VitalConnect, Inc. through its wholly owned subsidiary, iRhythm Technologies, Inc. VitalConnect is now a direct wholly owned subsidiary of iRhythm Technologies and an indirect wholly owned subsidiary of iRhythm Holdings. The acquisition adds mobile cardiac telemetry and multi-vitals monitoring capabilities and extends iRhythm’s portfolio across ambulatory, inpatient and hospital-to-home care.
Cash consideration was $237.5 million, subject to customary adjustments and funded from iRhythm’s balance sheet, plus up to 423,334 shares issued in connection with closing. iRhythm also provided VitalConnect $10.0 million in working capital funding between signing and closing. The transaction is expected to enhance iRhythm’s revenue growth rate beginning in 2027 while preserving its previously communicated 15% adjusted EBITDA margin target for 2027. iRhythm will provide updated 2026 financial guidance, including VitalConnect, on its third-quarter earnings call November 5, 2026. VitalConnect’s platform supports up to 30-day patient monitoring and up to 11 physiological parameters.
1 point · 0 major0 major · 0 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.iRhythm expects the acquisition to enhance its revenue growth rate beginning in 2027 while preserving its previously communicated 15% adjusted EBITDA margin target for 2027.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Cash consideration: $237.5 million
Shares issued in connection with closing: Up to 423,334 shares
Working capital funding: $10.0 million
+3 more
6 metrics
Cash consideration
$237.5 million
Subject to customary adjustments; funded from iRhythm’s balance sheet
Shares issued in connection with closing
Up to 423,334 shares
Acquisition consideration
Working capital funding
$10.0 million
Provided to VitalConnect between signing and closing
Adjusted EBITDA margin target
15%
Previously communicated target for 2027
Patient monitoring
Up to 30 days
VitalConnect platform capability
Physiological parameters
Up to 11
VitalConnect platform monitoring capability
Key Terms
mobile cardiac telemetry (MCT), adjusted EBITDA margin, four-in-one functionality, physiological parameters
4 terms
mobile cardiac telemetry (MCT) medical
"complementary mobile cardiac telemetry (MCT) capabilities"
Mobile cardiac telemetry is a wearable system that continuously records a person’s heart rhythm and sends the data in real time to a monitoring service, like a live security camera for the heart. Investors care because it improves detection and diagnosis of intermittent heart problems, drives demand for monitoring devices and services, affects reimbursement and clinical adoption, and therefore influences revenue and growth prospects for companies in cardiac monitoring and telehealth.
adjusted EBITDA margin financial
"adjusted EBITDA margin target of 15% for 2027"
Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.
four-in-one functionality technical
"four-in-one functionality, flexible service models and live look-in"
physiological parameters medical
"monitor up to 11 physiological parameters"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IRTC pay to acquire VitalConnect?
Cash consideration was $237.5 million, subject to customary adjustments, plus up to 423,334 shares issued in connection with closing. iRhythm also provided VitalConnect $10.0 million in working capital funding between signing and closing.
What does IRTC expect from the VitalConnect acquisition in 2027?
The transaction is expected to enhance iRhythm’s revenue growth rate beginning in 2027 while preserving its previously communicated 15% adjusted EBITDA margin target for 2027.
What monitoring features does VitalConnect’s platform offer?
VitalConnect’s platform offers up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. It can monitor up to 11 physiological parameters.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 5, 2026
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive office) (Zip Code)
(415 ) 632-5700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On October 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), issued a press release announcing the completion of the previously announced acquisition of Vital Connect, Inc., a Delaware corporation (the “Vital Connect”), by iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (the “Acquiror”). Following the acquisition, Vital Connect became a direct wholly owned subsidiary of the Acquiror and an indirect wholly owned subsidiary of the Company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits. | ||||
| Exhibit No. | Description | |||||||||||||||||||
| 99.1 | Press release issued by iRhythm Holdings, Inc., dated as of October 5, 2026. | |||||||||||||||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IRHYTHM HOLDINGS, INC. | |||||||||||
Date: October 5, 2026 | By: | /s/ Daniel Wilson | |||||||||
| Daniel Wilson | |||||||||||
| Chief Financial Officer | |||||||||||
iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care. iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect's growth and expand customer access. Transaction is expected to enhance iRhythm's revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated 15% adjusted EBITDA margin target for 2027. SAN FRANCISCO, October 5, 2026 - iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring. “Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.” “Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology,” said Peter Van Haur, Chief Executive Officer of VitalConnect. “By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.” VitalConnect’s cardiac monitoring platform supports multiple modalities, including complementary MCT capabilities. The VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. VitalConnect’s platform also has the capability to monitor up to 11 physiological parameters, advancing iRhythm’s multi-vitals strategy beyond traditional ambulatory cardiac monitoring. Together with iRhythm’s end-to-end cardiac monitoring service, the combination creates a broader portfolio designed to serve distinct customer workflows as well as clinician and patient needs. Strategic Fit and Financial Benefit The acquisition immediately expands iRhythm's capabilities across ambulatory cardiac monitoring, including MCT, creating a broader portfolio to serve diverse clinical needs. The combination also creates meaningful commercial acceleration opportunities by leveraging iRhythm's scale, customer relationships and go-to-market capabilities. Further, the addition of VitalConnect broadens iRhythm's addressable market across the continuum of care, extending its reach into inpatient, remote and hospital-to-home settings. The transaction also brings together complementary technology, data and workflow capabilities that are expected to accelerate innovation and enhance customer solutions. Together, these benefits strengthen iRhythm's long-term growth profile and position the company to serve more clinicians, customers and patients across a broader range of care settings. As previously announced, the acquisition is expected to enhance iRhythm’s revenue growth rate, while preserving its previously communicated adjusted EBITDA margin target of 15% for 2027. Exhibit 99.1
Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and up to 423,334 shares issued in connection with closing. In addition, iRhythm provided $10.0 million of working capital funding to VitalConnect between signing and closing. iRhythm will provide updated 2026 financial guidance, inclusive of VitalConnect, during its third quarter earnings call on November 5th, 2026. About iRhythm Holdings, Inc. iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining its Zio® wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the anticipated strategic, commercial, operational and financial benefits of the transaction; the ability to expand into new markets, care settings, customer categories and commercial partnerships; the potential to take advantage of and accelerate VitalConnect's growth, deepen customer relationships and realize cross-selling opportunities; future product development, regulatory approvals and commercialization; the success of integration and the retention of key employees; the anticipated growth of the mobile cardiac telemetry category; and the expected impact on revenue growth, adjusted EBITDA and adjusted EBITDA margin. These statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will” and similar expressions. Forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially, including challenges in integrating VitalConnect and realizing anticipated benefits and synergies on the expected timeline or at all; business disruption or diversion of management’s attention; changes in market demand, reimbursement, competition or regulation; product development or regulatory delays; the loss of key VitalConnect employees, customers or partners; and unforeseen liabilities and future expenditures associated with the transaction; and the risks described under “Risk Factors” and elsewhere in iRhythm's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed on August 6, 2026. These forward-looking statements speak only as of the date of this press release. iRhythm undertakes no obligation to update them except as required by law. Contacts Investors Media Francis Pruell investors@irhythmtech.com Kassandra Perry mediarelations@irhythmtech.com